Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia

Zheng Xia(Roswell Park Comprehensive Cancer Center), Meir Wetzler, Maria R. Baer(University of Maryland, Baltimore), Maurice Barcos(Roswell Park Comprehensive Cancer Center), Kathleen Donohue(Roswell Park Comprehensive Cancer Center), Heinz Baumann(Roswell Park Comprehensive Cancer Center), Anne Marie W. Block(Roswell Park Comprehensive Cancer Center), Laurie Ford(Roswell Park Comprehensive Cancer Center), David Lawrence(VA Connecticut Healthcare System), Sheila N.J. Sait(Roswell Park Comprehensive Cancer Center)
Leukemia Research
June 1, 2001
10.1016/s0145-2126(00)00158-2
Cited by 49

Related Papers

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Granulocytic sarcoma: A clinicopathologic study of 61 biopsied cases
|Cancer|1981|974
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
|The Lancet Oncology|2017|493